Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Stem cell factor inhibitor
US9353178B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9353178-B2 |
| Application number | US-201313937852-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 9, 2013 |
| Priority date | Jan 10, 2011 |
| Publication date | May 31, 2016 |
| Grant date | May 31, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
First claim
Opening claim text (preview).
We claim: 1. An anti-stem cell factor antibody that specifically binds to stem cell factor isoform b relative to stem cell factor isoform a or an antigen-binding antibody fragment that specifically binds to stem cell factor isoform b relative to stem cell factor isoform a. 2. The anti-stem cell factor antibody or the antigen-binding antibody fragment of claim 1 wherein the antibody or the antigen-binding antibody fragment specifically binds to a protein comprising an amino acid sequence provided by SEQ ID NO: 4 or antibody-binding fragment thereof. 3. The anti-stem cell factor antibody or the antigen-binding antibody fragment of claim 1 wherein the antibody is a monoclonal antibody or the antigen-binding antibody fragment is a fragment of a monoclonal antibody. 4. The anti-stem cell factor antibody or the antigen-binding antibody fragment of claim 1 wherein the antibody is a polyclonal antibody. 5. The anti-stem cell factor antibody or the antigen-binding antibody fragment of claim 1 wherein the antibody is a humanized antibody or the antigen-binding antibody fragment is a fragment of a humanized antibody. 6. The anti-stem cell factor antibody or the antigen-binding antibody fragment of claim 1 wherein the antibody or antigen-binding antibody fragment is a Fab, a Fab′, a F(ab′), a Fv fragment, a scFv fragment, or a linear antibody. 7. A composition comprising the anti-stem cell factor antibody or the antigen-binding antibody fragment of claim 1 . 8. The composition of claim 7 further comprising a stem cell factor isoform b polypeptide. 9. The composition of claim 8 wherein the antibody or antigen-binding antibody fragment is bound to the stem cell factor isoform b polypeptide. 10. The composition of claim 7 comprising a physiologically appropriate solution for administration to a subject. 11. The composition of claim 10 formulated for administration into an airway of a subject.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title
General protective or antinoxious agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9353178B2 cover?
- Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases.
- Who is the assignee on this patent?
- Univ Michigan
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).